The tech company’s data platform will be implemented into the genomic research department’s workflow.
Genomics research is growing in importance for the pharma industry with each passing year. One issue that researchers face, however, is the significant amount of data that genomics research generates and requires. Not surprisingly, recent advancements in data technology have caught the eye of many in the life sciences industry.
Texas A&M Health and BurstIQ announced that they have formed a partnership which will leverage BurstIQ’s LifeGraph management platform to improve genomic data governance. The Texas A&M Health PROVENANCE clinicogenomics registry programs will be the primary benefactors of this partnership.
In a press release, Texas A&M’s executive director of clinical, translational, and industry collaborations at the Institute of Biosciences and Technology, Center for Precision and Genomic Medicine Rick Silva, PhD, said, “LifeGraph provides a unique foundation for a modern, data-driven, and scalable approach to collaborative genomics research. By securely linking clinical and non-clinical data in knowledge graphs and allowing patients to make informed decisions about participating in clinical research across time and the patient journey, we can better support patients, institutional data stewards, and enable researchers to derive more value from data. Now we can harness the power of real-world data to transform clinicogenomics research."
In the same press release, BurstIQ CEO Frank Ricotta said, “We are incredibly excited to partner with Texas A&M Health on this revolutionary initiative. LifeGraph's secure handling of sensitive healthcare data opens up new possibilities for transforming research and positively impacting the lives of patients."
BurstIQ has recently partnered with other organizations in healthcare. In July, the company announced that it had formed a partnership with LiteHouse Health, a healthcare staffing platform.
In a press release, Litehouse Health co-founder and chief nursing officer Dr. Ellen Kuhnert said, “At Litehouse Health, we are committed to responding to the needs of our hospital system partners, unlocking local talent, and caring for patients, all with quality as our guide and a commitment to care in the communities we serve. By partnering with BurstIQ to create Litehouse solutions, we're empowering clinicians with the flexibility they deserve while ensuring hospitals have immediate access to the highly qualified talent they need."
In the same press release, Ricotta added, “By utilizing connected nurse profiles, verified credentials, a knowledge graph-powered scheduling ecosystem, and app accelerators, Litehouse Health is maximizing the unique capabilities of the LifeGraph Platform. It's incredibly rewarding to see our advanced data management approach bring such innovative solutions to life."
Also, in March of this year, BurstIQ announced a partnership with Maryville University.3 Once again, the tech company’s data platform was at the center of the partnership.
In a press release, BurstIQ’s chief strategy officer Amber Hartley said, “This partnership reflects Maryville University's unwavering commitment to creating best-in-class administrative operations and student experiences. LifeGraph is uniquely suited to help the university achieve its vision and stay ahead as higher education evolves."
Maryvill University president Mark Lombardi added, “With BurstIQ and the LifeGraph platform, we can support and empower students by managing their educational information in a more holistic way while ensuring their data stays private and secure. LifeGraph provides us with a student-centric data management ecosystem that aligns with Maryville's commitment to providing access and opportunity by empowering success for all students."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.